Can an Immune-Boosting antibody extend life in advanced lung cancer?

NCT ID NCT03789604

NEW Completed Disease control Sponsor: CStone Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Aug 18, 2026 · Last updated Aug 18, 2026

Summary

This trial is investigating whether adding an experimental antibody called CS1001 to standard chemotherapy can help people with stage IV non-small cell lung cancer. The study compares the combination against chemotherapy alone in patients who have not yet received treatment for advanced disease. The goal is to see if the antibody slows cancer progression and improves survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CS1001, an experimental monoclonal antibody, combined with standard platinum-based chemotherapy
What this could lead to: If effective, this combination could become a new first-line treatment option for stage IV non-small cell lung cancer, potentially extending the time before the cancer worsens and improving overall survival.
What could go wrong: This is an early-phase test in a specific patient group, and the added antibody may not improve outcomes or could increase side effects. Results are not yet available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON SMALL CELL LUNG CANCER

Contacts and locations

Locations

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.